Lipopolysaccharide binding protein and sCD14 as risk markers of stroke-associated pneumonia.
Biomarker
Inflammation
LBP
Pneumonia
Stroke
sCD14
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 05 2021
15 05 2021
Historique:
received:
24
11
2020
revised:
02
02
2021
accepted:
23
02
2021
pubmed:
7
3
2021
medline:
26
5
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
To determine the utility of lipopolysaccharide binding protein (LBP) and soluble CD14 (sCD14) as risk markers of stroke-associated pneumonia (SAP). We included 331 stroke patients. The plasma levels of LBP (median: 19.4 vs 15.3 μg/mL, P < 0.01) and sCD14 (median: 1.5 vs 1.4 μg/mL, P = 0.04) were elevated in SAP. In multivariate analysis, a higher level of LBP (OR: 1.09, 95%CI: 1.05-1.13), but not sCD14 (OR: 2.16, 0.94-4.97), was associated with SAP. The addition of LBP or sCD14 to the clinical model did not improve its discriminatory ability. Our results suggest the modest value of studied biomarkers for SAP prediction.
Identifiants
pubmed: 33676085
pii: S0165-5728(21)00059-X
doi: 10.1016/j.jneuroim.2021.577532
pii:
doi:
Substances chimiques
Acute-Phase Proteins
0
Biomarkers
0
Carrier Proteins
0
Lipopolysaccharide Receptors
0
Membrane Glycoproteins
0
lipopolysaccharide-binding protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577532Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.